361 related articles for article (PubMed ID: 28142305)
1. Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents.
Altarifi AA; David B; Muchhala KH; Blough BE; Akbarali H; Negus SS
J Psychopharmacol; 2017 Jun; 31(6):730-739. PubMed ID: 28142305
[TBL] [Abstract][Full Text] [Related]
2. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine.
DeWire SM; Yamashita DS; Rominger DH; Liu G; Cowan CL; Graczyk TM; Chen XT; Pitis PM; Gotchev D; Yuan C; Koblish M; Lark MW; Violin JD
J Pharmacol Exp Ther; 2013 Mar; 344(3):708-17. PubMed ID: 23300227
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.
Schwienteck KL; Faunce KE; Rice KC; Obeng S; Zhang Y; Blough BE; Grim TW; Negus SS; Banks ML
Neuropharmacology; 2019 May; 150():200-209. PubMed ID: 30660628
[TBL] [Abstract][Full Text] [Related]
4. The Utilization of Mu-Opioid Receptor Biased Agonists: Oliceridine, an Opioid Analgesic with Reduced Adverse Effects.
Urits I; Viswanath O; Orhurhu V; Gress K; Charipova K; Kaye AD; Ngo A
Curr Pain Headache Rep; 2019 Mar; 23(5):31. PubMed ID: 30880365
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain.
Chen XT; Pitis P; Liu G; Yuan C; Gotchev D; Cowan CL; Rominger DH; Koblish M; Dewire SM; Crombie AL; Violin JD; Yamashita DS
J Med Chem; 2013 Oct; 56(20):8019-31. PubMed ID: 24063433
[TBL] [Abstract][Full Text] [Related]
6. The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats.
Austin Zamarripa C; Edwards SR; Qureshi HN; Yi JN; Blough BE; Freeman KB
Drug Alcohol Depend; 2018 Nov; 192():158-162. PubMed ID: 30261403
[TBL] [Abstract][Full Text] [Related]
7. Role of β-arrestin-2 in short- and long-term opioid tolerance in the dorsal root ganglia.
Muchhala KH; Jacob JC; Dewey WL; Akbarali HI
Eur J Pharmacol; 2021 May; 899():174007. PubMed ID: 33705801
[TBL] [Abstract][Full Text] [Related]
8. The G Protein Signal-Biased Compound TRV130; Structures, Its Site of Action and Clinical Studies.
Miyano K; Manabe S; Komatsu A; Fujii Y; Mizobuchi Y; Uezono E; Ohshima K; Nonaka M; Kuroda Y; Narita M; Uezono Y
Curr Top Med Chem; 2020; 20(31):2822-2829. PubMed ID: 33115393
[TBL] [Abstract][Full Text] [Related]
9. APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty.
Singla NK; Skobieranda F; Soergel DG; Salamea M; Burt DA; Demitrack MA; Viscusi ER
Pain Pract; 2019 Sep; 19(7):715-731. PubMed ID: 31162798
[TBL] [Abstract][Full Text] [Related]
10. Usefulness for the combination of G-protein- and β-arrestin-biased ligands of μ-opioid receptors: Prevention of antinociceptive tolerance.
Mori T; Kuzumaki N; Arima T; Narita M; Tateishi R; Kondo T; Hamada Y; Kuwata H; Kawata M; Yamazaki M; Sugita K; Matsuzawa A; Baba K; Yamauchi T; Higashiyama K; Nonaka M; Miyano K; Uezono Y; Narita M
Mol Pain; 2017; 13():1744806917740030. PubMed ID: 29056067
[TBL] [Abstract][Full Text] [Related]
11. Further investigation of the rapid-onset and short-duration action of the G protein-biased μ-ligand oliceridine.
Mori T; Takemura Y; Arima T; Iwase Y; Narita M; Miyano K; Hamada Y; Suda Y; Matsuzawa A; Sugita K; Matsumura S; Sasaki S; Yamauchi T; Higashiyama K; Uezono Y; Yamazaki M; Kuzumaki N; Narita M
Biochem Biophys Res Commun; 2021 Jan; 534():988-994. PubMed ID: 33139013
[TBL] [Abstract][Full Text] [Related]
12. Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics.
Pedersen MF; Wróbel TM; Märcher-Rørsted E; Pedersen DS; Møller TC; Gabriele F; Pedersen H; Matosiuk D; Foster SR; Bouvier M; Bräuner-Osborne H
Neuropharmacology; 2020 Apr; 166():107718. PubMed ID: 31351108
[TBL] [Abstract][Full Text] [Related]
13. The G-protein-biased agents PZM21 and TRV130 are partial agonists of μ-opioid receptor-mediated signalling to ion channels.
Yudin Y; Rohacs T
Br J Pharmacol; 2019 Sep; 176(17):3110-3125. PubMed ID: 31074038
[TBL] [Abstract][Full Text] [Related]
14. TRV130 partial agonism and capacity to induce anti-nociceptive tolerance revealed through reducing available μ-opioid receptor number.
Singleton S; Baptista-Hon DT; Edelsten E; McCaughey KS; Camplisson E; Hales TG
Br J Pharmacol; 2021 Apr; 178(8):1855-1868. PubMed ID: 33555037
[TBL] [Abstract][Full Text] [Related]
15. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform.
Vasudevan L; Vandeputte M; Deventer M; Wouters E; Cannaert A; Stove CP
Biochem Pharmacol; 2020 Jul; 177():113910. PubMed ID: 32179045
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological, and structural explorations of a series of μ-opioid receptor (MOR) agonists with high G protein signaling bias.
Yang Y; Wang Y; Zuo A; Li C; Wang W; Jiang W; Zhang X; Che X; Zhang Y; Wu W; Cen X; Wang H; Tian J
Eur J Med Chem; 2022 Jan; 228():113986. PubMed ID: 34802839
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Characters of Oliceridine, a μ-Opioid Receptor G-Protein-Biased Ligand in Mice.
Liang DY; Li WW; Nwaneshiudu C; Irvine KA; Clark JD
Anesth Analg; 2019 Nov; 129(5):1414-1421. PubMed ID: 30044299
[TBL] [Abstract][Full Text] [Related]
18. Mu-opioid Receptor (MOR) Biased Agonists Induce Biphasic Dose-dependent Hyperalgesia and Analgesia, and Hyperalgesic Priming in the Rat.
Araldi D; Ferrari LF; Levine JD
Neuroscience; 2018 Dec; 394():60-71. PubMed ID: 30342200
[TBL] [Abstract][Full Text] [Related]
19. Safety evaluation of oliceridine for the management of postoperative moderate-to-severe acute pain.
Tan HS; Habib AS
Expert Opin Drug Saf; 2021 Nov; 20(11):1291-1298. PubMed ID: 34370562
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potentially biased agonists of mu-opioid receptor (MOR) through molecular docking, pharmacophore modeling, and MD simulation.
Jiang X; Li S; Zhang H; Wang LL
Comput Biol Chem; 2021 Feb; 90():107405. PubMed ID: 33184004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
